Skip to main content

In hypercholesterolemia, adding inclisiran to individually optimized lipid-lowering therapy improved LDL-C levels at 90 d.

Publication ,  Journal Article
Allan, T; Newby, LK; ACP Journal Club Editorial Team at McMaster University
Published in: Ann Intern Med
January 2026

GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

Duke Scholars

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

January 2026

Volume

179

Issue

1

Start / End Page

JC9

Location

United States

Related Subject Headings

  • RNA, Small Interfering
  • Middle Aged
  • Male
  • Hypercholesterolemia
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • General & Internal Medicine
  • Female
  • Drug Therapy, Combination
  • Cholesterol, LDL
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Allan, T., Newby, L. K., & ACP Journal Club Editorial Team at McMaster University. (2026). In hypercholesterolemia, adding inclisiran to individually optimized lipid-lowering therapy improved LDL-C levels at 90 d. Ann Intern Med, 179(1), JC9. https://doi.org/10.7326/ANNALS-25-05115-JC
Allan, Tess, L Kristin Newby, and ACP Journal Club Editorial Team at McMaster University. “In hypercholesterolemia, adding inclisiran to individually optimized lipid-lowering therapy improved LDL-C levels at 90 d.Ann Intern Med 179, no. 1 (January 2026): JC9. https://doi.org/10.7326/ANNALS-25-05115-JC.
Allan T, Newby LK, ACP Journal Club Editorial Team at McMaster University. In hypercholesterolemia, adding inclisiran to individually optimized lipid-lowering therapy improved LDL-C levels at 90 d. Ann Intern Med. 2026 Jan;179(1):JC9.
Allan, Tess, et al. “In hypercholesterolemia, adding inclisiran to individually optimized lipid-lowering therapy improved LDL-C levels at 90 d.Ann Intern Med, vol. 179, no. 1, Jan. 2026, p. JC9. Pubmed, doi:10.7326/ANNALS-25-05115-JC.
Allan T, Newby LK, ACP Journal Club Editorial Team at McMaster University. In hypercholesterolemia, adding inclisiran to individually optimized lipid-lowering therapy improved LDL-C levels at 90 d. Ann Intern Med. 2026 Jan;179(1):JC9.

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

January 2026

Volume

179

Issue

1

Start / End Page

JC9

Location

United States

Related Subject Headings

  • RNA, Small Interfering
  • Middle Aged
  • Male
  • Hypercholesterolemia
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • General & Internal Medicine
  • Female
  • Drug Therapy, Combination
  • Cholesterol, LDL